00:41:08 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-02-14 Bokslutskommuniké 2023
2023-11-15 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-05-16 Kvartalsrapport 2023-Q1
2023-05-11 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-11-23 Kvartalsrapport 2022-Q3
2022-08-24 Kvartalsrapport 2022-Q2
2022-05-16 Kvartalsrapport 2022-Q1
2022-05-13 Ordinarie utdelning NYKD 0.00 NOK
2022-05-12 Årsstämma 2022
2022-03-31 Bokslutskommuniké 2021
2021-12-22 Extra Bolagsstämma 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-12 Kvartalsrapport 2021-Q1
2021-05-06 Ordinarie utdelning NYKD 0.00 NOK
2021-05-05 Årsstämma 2021
2021-04-21 Bokslutskommuniké 2020
2020-11-17 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-07-07 Split NYKD 1:5
2020-07-06 Extra Bolagsstämma
2020-05-12 Kvartalsrapport 2020-Q1
2020-04-22 Extra Bolagsstämma

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
Nykode Therapeutics är verksamma inom bioteknik. Bolaget är idag specialiserade inom forskning och utveckling av immunologiska terapier och vacciner. Lösningarna används huvudsakligen för behandling av patienter med cancersjukdomar samt övriga allvarliga hälsotillstånd som kräver långsiktig behandling. Störst verksamhet återfinns inom den europeiska marknaden.
2022-06-02 15:45:00
Oslo, Norway, June 2, 2022 - Nykode Therapeutics ASA (Euronext Growth (Oslo):
NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and
development of vaccines and novel immunotherapies, today announced that its
conversion to a public limited liability company has been registered.

Reference is made to the stock exchange announcement made on May 12, 2022 by
Nykode Therapeutics ASA regarding the annual general meeting held the same date.
The resolutions made by the general meeting, including, inter alia, the
conversion of the company into a public limited liability company, change of
company name and, consequently, necessary amendments to the articles of
association, have now been registered with the Norwegian Register of Business
Enterprises. The new name of the company is Nykode Therapeutics ASA.


Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of vaccines and novel immunotherapies for the
treatment of cancer and infectious diseases. Nykode's modular vaccine technology
specifically targets antigens to Antigen Presenting Cells, which are essential
for inducing rapid, strong and long-lasting antigen specific immune responses
and eliciting efficacious clinical responses.

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus (HPV)-16 induced malignancies which
demonstrated positive interim efficacy and safety results from its Phase II
trial for the treatment of cervical cancer